Will HealthCare And Biotech Resume Market Leadership?

Biotech ETFs XBI and IBB are outperforming so far this year.  It’s not too surprising if you use Stage Analysis since we know that bear markets are authors of bull markets, and biotech was one of the worst performing sectors of 2016.  I take a look at XBI and IBB from a Stage Analysis perspective in this video and discuss what I’m looking for as the second quarter of 2017 starts.